Table 2.
KEGG Enrichment Analysis Results.
| ID | Description | P |
|---|---|---|
| hsa05202 | Transcriptional misregulation in cancer | 0.0010 |
| hsa04930 | Type II diabetes mellitus | 0.0029 |
| hsa04931 | Insulin resistance | 0.0044 |
| hsa04152 | AMPK signaling pathway | 0.0068 |
| hsa04920 | Adipocytokine signaling pathway | 0.0091 |
| hsa00562 | Inositol phosphate metabolism | 0.0106 |
| hsa00030 | Pentose phosphate pathway | 0.0150 |
| hsa05410 | Hypertrophic cardiomyopathy (HCM) | 0.0150 |
| hsa00051 | Fructose and mannose metabolism | 0.0180 |
| hsa04211 | Longevity regulating pathway | 0.0181 |
| hsa04022 | cGMP-PKG signaling pathway | 0.0187 |
| hsa04925 | Aldosterone synthesis and secretion | 0.0221 |
| hsa04960 | Aldosterone-regulated sodium reabsorption | 0.0224 |
| hsa04070 | Phosphatidylinositol signaling system | 0.0239 |
| hsa00290 | Valine, leucine and isoleucine biosynthesis | 0.0249 |
| hsa04510 | Focal adhesion | 0.0356 |
| hsa00280 | Valine, leucine and isoleucine degradation | 0.0363 |
| hsa04270 | Vascular smooth muscle contraction | 0.0400 |
| hsa04068 | FOXO signaling pathway | 0.0496 |